News

Arzerra is indicated for the treatment of chronic lymphocytic leukaemia (CLL) in patients who are refractory to fludarabine and alemtuzumab. GSK claimed that Arzerra is a new monoclonal

Through this agreement, BioServe, a provider of CLIA-certified genetic testing services, will provide NGC Medical with a full complement of CLIA-certified personalized genomics services, including DNA extraction, QC

ASG-5ME is an ADC composed of a fully human antibody directed to AGS-5, a new cancer target discovered by Agnes. The antibody is attached to a potent, synthetic

As per the collaboration, which was signed on March 2008, the companies will leverage a number of Silence’s proprietary lipid delivery and targeting technologies to develop new delivery

Bosch Packaging Technology claimed that the machine features automatic troubleshooting and has the capability to fill a combination of powders, pellets, liquids and a range of tablets. The

The Genous Bio-engineered Cobalt Chromium Stent combines OrbusNeich’s patented endothelial progenitor cell (EPC) capture technology Genous with a L605 cobalt chromium bare metal stent based on the company’s

Genzyme posted a net loss of $114.95m for the first quarter 2010, or $0.43 per diluted share, compared to net income of $195.48m, or $0.70 per diluted share,

Onko-Sure is a simple, non-invasive, patent-pending and regulatory-approved IVD test used for the detection, screening, and monitoring of various types of cancer. The test enables physicians and healthcare

As per the terms of the agreement, Genentech has rights to use Seattle Genetics’ ADC technology with antibodies against targets selected by Genentech. Genentech will be responsible for